Abstract

The mitogen-inducible gene 6 (MIG6) is an adaptor protein widely expressed in vascular endothelial cells. However, it remains unknown thus far whether it plays a role in angiogenesis. Here, using comprehensive in vitro and in vivo model systems, we unveil a potent anti-angiogenic effect of MIG6 in retinal development and neovascularization and the underlying molecular and cellular mechanisms. Loss of function assays using genetic deletion of Mig6 or siRNA knockdown increased angiogenesis in vivo and in vitro, while MIG6 overexpression suppressed pathological angiogenesis. Moreover, we identified the cellular target of MIG6 by revealing its direct inhibitory effect on vascular endothelial cells (ECs). Mechanistically, we found that the anti-angiogenic effect of MIG6 is fulfilled by binding to SHC1 and inhibiting its phosphorylation. Indeed, SHC1 knockdown markedly diminished the effect of MIG6 on ECs. Thus, our findings show that MIG6 is a potent endogenous inhibitor of angiogenesis that may have therapeutic value in anti-angiogenic therapy.

Highlights

  • The blood vessel network is vital for both normal physiology and numerous diseases

  • mitogen-inducible gene 6 (MIG6) Is Expressed in Various Types of Vascular Endothelial Cells (ECs) From Different Human Organs

  • We found that MIG6 is expressed in endothelial cells (ECs) from various tissues/organs, including skin, liver, prostate, lung, heart muscle, eye, placenta, and testis (Supplementary Table 1), indicating a potential effect of MIG6 on ECs

Read more

Summary

Introduction

The blood vessel network is vital for both normal physiology and numerous diseases. Blood vessels transport oxygen and nutrient to tissues and cells required for their functions and maintenance, they have unique functions by serving as a regulator of vascular tone, organ development, immunity, and blood-organ communication (Karaman et al, 2018; Li and Carmeliet, 2018). The majority of the studies have focused on angiogenic factors. Much knowledge in this aspect has been gained and anti-angiogenic therapies targeting angiogenic factors, such as VEGF, have been used to treat patients with neovascular diseases (Apte et al, 2019). Decreased or the lack of the expression of anti-angiogenic factors may often be the reason of pathological neovascularization (Murugeswari et al, 2008; Zhang et al, 2020). Studying such endogenous anti-angiogenic molecules is of critical importance

Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call